A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 69-76

  Kuti, J L ^a   Dowzicky, M ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b PFIZER INC   (United States)

Author keywords

Antibiotics; Bacteria; Bacteria resistance; Glycylcycline; Pharmacology; Pneumonia; Respiratory; Tigecycline

Indexed keywords

BETA LACTAM; BETA LACTAM DERIVATIVE; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; AREA UNDER THE CURVE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG MECHANISM; ENTEROBACTER; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; KLEBSIELLA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; NONHUMAN; PNEUMONIA; PREVALENCE; PROBABILITY; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS;

EID: 41149167747     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.69     Document Type: Article

References (32)

1. Zhanel GG, Homenuik K, Nichol K, et al. Glycylcyclines: a comparative review with the tetracyclines. Drugs 2004;64(1):63-88.
2. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004;48(11):4479-4481.
3. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vivo activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006;50(10):3479-3484.
4. th Annual Meeting of IDSA. Infectious Diseases Society of America, Alexandria, VA, 2006; 75.
5. National Institutes of Health. Clinical Trial Registry. Available online at http://www.clinicaltrials.gov. Accessed November 7, 2006
6. Conte JE, Golden JA, Grace Kelly M, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25(6):523-529.
7. Saner FH, Heuer M, Rath P, et al. Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia. Liver Transplant 2006;12(11):1689-1692.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26(1):1-12.
9. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of anti-infectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003;22(11):982-992.
10. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA program. Crit Care Med 2005;33(10):2222-2227.
11. Deryke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of 6 intravenous β-lactams and 2 fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from U.S. intensive care units during 2004. Pharmacotherapy 2007;27(3):333-342.
12. Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother 2006;50(11):3701-3707.
13. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 2002;22(10):1216-1225.
14. Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48(12):4718-4724.
15. Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997;40(2):269-273.
16. Drusano GL, Plaisance KI, Forrest A, et al. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother 1987;31(9):1420-1422.
17. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51(6):1939-1945.
18. Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analysis of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008; 52 (1): 204-210.
19. Hoban DJ, Biendenbach DJ, Mutnick AH, Jones RN. Pathogen occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003;45(4):279-285.
20. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a Phase II/III dose for evernimicin and identification of a preclinical breakpoint. Antimicrob Agents Chemother 2001;45(1):13-22.
21. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Analysis of two double blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124(5):1789-1797.
22. Kuti J, Kiffer C, Mendes C, Nicolau D. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008; 14 (2); 116-123.
23. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45(10): 2793-2797.
24. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189(9): 1590-1597.
25. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in adult patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51(5): 1725-1730.
26. Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA program. Diagn Microbiol Infect Dis 2005; 53(4): 281-287.
27. Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents 2006; 28(1): 62-68.
28. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse E. Serum, tissue, and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58(6): 1221-1229.
29. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171(4): 388-416.
30. Van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother 2000; 44(4): 943-949.
31. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44(4): 79-86.
32. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health-Syst Pharm 2000; 57 (suppl 2): 84-89.